A Bio-Immunity Research and Discovery Company
Helping the body’s own immune system fight cancer
DC-MelVac: The Curevax vaccine against melanoma
Better treatment of cancer through innovation
CureVax is a bio-immunology research and discovery company engaged in developing cancer immunotherapeutic vaccines with the initial focus on melanoma.
The CureVax MelVac platform immunotherapeutic vaccine may provide clinicians with a new weapon in the armamentarium to fight cancer, to be used together with current medical and surgical treatment techniques, with the goal of prolonging patients’ survival and quality of life.
CureVax is an emerging cancer treatment method in which a patient’s tumor cells are sampled, grown in the laboratory, and destroyed in a specific way to expose that cancer’s vulnerabilities.